B of A Securities Reiterates Buy Rating on GRDN
B of A Securities reaffirms its buy rating for GRDN with a target price of $47, a 10.80% upside from the current price.
Key Points
- On June 17, 2026, B of A Securities reiterated its buy rating for GRDN with a price target of $47.
- B of A Securities's $47 price target implies 10.80% upside from Guardian Pharmacy Services, Inc.'s ($GRDN) current $42.42 share price.
- GRDN shares are trading at $42.42, with several institutional investors adjusting their positions recently.
- Other analysts, including Oppenheimer and Truist Securities, also maintain buy ratings with targets ranging from $38 to $43.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, B of A Securities reiterated its buy rating on GRDN, setting a price target of $47. Analyst Allen Lutz maintained his positive outlook on the stock.
Other Institutional Activity in GRDN
Driehaus Capital Management LLC increased its stake in GRDN by 82,646 shares, bringing its total to 589,121 shares valued at about $22.2 million. Silvercrest Asset Management Group LLC, on the other hand, reduced its holdings by 397,635 shares, leaving it with 374,946 shares worth approximately $14.1 million. Peregrine Capital Management LLC also trimmed its position by 19,453 shares, now holding 201,603 shares valued at $7.6 million. Ranger Investment Management, L.P. made a small reduction of 475 shares, ending with 167,190 shares worth $6.3 million. Meanwhile, Legato Capital Management LLC opened a new position with 58,890 shares valued at around $2.2 million.
Guardian Pharmacy Services, Inc. Stock Up 14.5%
Shares of GRDN are currently trading at $42.42. The stock has seen various analyst ratings, with B of A Securities setting a target price of $47. Other analysts, such as Oppenheimer and Truist Securities, have maintained buy ratings with price targets ranging from $38 to $43.
Analysts Set New Price Targets
On June 17, 2026, B of A Securities maintained its buy rating on GRDN with a $47 price target. Oppenheimer previously reaffirmed its buy rating on May 7, 2026, with a $43 target. Truist Securities also maintained a buy rating on April 13, 2026, setting a target of $43. Jefferies initiated coverage with a buy rating and a $44 target back on March 30, 2026.
Bottom Line
B of A Securities' reiterated buy rating and $47 target price reflect continued confidence in GRDN's prospects. Various institutional investors have been adjusting their positions in the company, indicating diverse views on its potential. Analysts broadly maintain a positive outlook, with multiple buy ratings and target prices in the low-to-mid $40s.
Get Guardian Pharmacy Services, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.